甲基3-羟基-1-吡咯烷羧酸酯 | 83487-19-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 甲基3-羟基-1-吡咯烷羧酸酯
• 英文名称: N-carbomethoxy-3-hydroxypyrrrolidine
• 英文别名: Methyl 3-hydroxypyrrolidine-1-carboxylate
• CAS: 83487-19-8
• 化学式: C₆H₁₁NO₃
• 分子量: 145.158
• InChiKey: UTAOVTFSCMSWNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲基3-羟基-1-吡咯烷羧酸酯 在 乙醇 、 sodium acetate 、 sodium hydride 、 对甲苯磺酸 、 三乙胺 、 pyridinium chlorochromate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 0.33h， 生成 diethyl 2-(1-methoxycarbonylpyrrolidin-3-yl)-2-[(E)-4-oxobut-2-enyl]propanedioate
  参考文献：
  名称：

  Room Temperature Hydroalkylation of Electron-Deficient Olefins:  sp³ C−H Functionalization via a Lewis Acid-Catalyzed Intramolecular Redox Event

  摘要：

  A practical method for the intramolecular hydroalkylation of electron-deficient olefins has been developed. The direct transformation of benzylic, tertiary, and sterically hindered secondary sp3 C-H bonds into C-C bonds under the action of a catalytic amount of a variety of Lewis acids is described. The mechanism of these transformations is proposed to involve a tandem hydride transfer/cyclization sequence.

  DOI：

  10.1021/ja053337f
• 作为产物：
  描述：

  甲基2-甲氧基-1-吡咯烷羧酸酯 在 sodium tetrahydroborate 、 双氧水 、 氯化铵 作用下， -20.0 ℃ 、13.33 kPa 条件下， 反应 10.0h， 生成 甲基3-羟基-1-吡咯烷羧酸酯
  参考文献：
  名称：

  Electroorganic chemistry. 60. Electroorganic synthesis of enamides and enecarbamates and their utilization in organic synthesis

  摘要：

  DOI：

  10.1021/ja00388a037

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DU CANAL NAV, ET LEURS UTILISATIONS
  申请人：MERCK PATENT GMBH

  公开号：WO2015130905A1

  公开（公告）日：2015-09-03

  The present invention relates to heterocyclic compounds of formula (I) wherein: Z1 is C(R)(R), C(O), C(S), or C(NR); 2 Z is C(R)(R), 0, S, SO, S02, or NR; X is -O-, -S-, -S02-, -SO-, -C(O)-, -C02-, -C(O)N(R)-, -NRC(O)-, -NRC(O) N(R)-, -NRSO2-, or -N(R)-; or X is absent; A is an optionally substituted C1_6 aliphatic, C5-10 aryl, 3-8 membered saturated or partially unsaturated carbocyclic ring, 3-7 membered heterocylic ring, or a 5-6 membered heteroaryl ring; Y is -CH2-, -O-, -S-, -S02-, -SO-, -C(O)-, -C02-, -C(O)N(R)-, -NRC(O)-, - NRC(O)N(R)-, -NRS02-, or -N(R)-; B is an optionally substituted C5-10 aryl or 5-6 membered heteroaryl ring; m is 0, 1, 2, or 3; n is 0, 1, 2, or 3; q is 0, 1, 2, or 3; and r is 1 or 2; and pharmaceutically acceptable compositions thereof, useful as Navl.6 inhibitors.

  本发明涉及具有以下结构的杂环化合物（I）：其中：Z1为C（R）（R）、C（O）、C（S）或C（NR）；Z为C（R）（R）、0、S、SO、SO2或NR；X为-O-、-S-、-SO2-、-SO-、-C（O）-、-CO2-、-C（O）N（R）-、-NRC（O）-、-NRC（O）N（R）-、-NRSO2-或-N（R）-；或X为空；A为可选择取代的C1_6脂肪族、C5-10芳基、3-8成员饱和或部分不饱和的碳环、3-7成员杂环环或5-6成员杂芳基环；Y为-CH2-、-O-、-S-、-SO2-、-SO-、-C（O）-、-CO2-、-C（O）N（R）-、-NRC（O）-、-NRC（O）N（R）-、-NRSO2-或-N（R）-；B为可选择取代的C5-10芳基或5-6成员杂芳基环；m为0、1、2或3；n为0、1、2或3；q为0、1、2或3；r为1或2；以及其药用可接受的组合物，用作Navl.6抑制剂。
• Benzimidazole derivatives
  申请人：——

  公开号：US20040044056A1

  公开（公告）日：2004-03-04

  This invention relates to the compounds represented by a general formula [I]: 1 [in which A 1 and A 2 represent optionally fluorine-substituted methine or the like; B represents halogen, cyano, lower alkyl or the like; D represents optionally substituted heterocyclic group or the like; and G represents C 3 -C 20 aliphatic group such as alicyclic group]. These compounds inhibit nociceptin activities due to their high affinity to nociceptin receptor, and are useful as analgesic, antiobestic, corebral function improver, drugs for treatment of alzheimer's disease and dementia, remedies for schizophrenia and neurodegenerative diseases, antidepressant, remedies for diabetes insipidus, polyuria, hypotension and so on.

  本发明涉及由一般式[I]表示的化合物：1[其中，A1和A2表示选择性氟代甲基或类似物；B表示卤素，氰基，低碳烷基或类似物；D表示选择性取代的杂环基团或类似物；G表示C3-C20脂肪族基团，例如脂环族基团]。这些化合物由于对痛觉受体具有高亲和力而抑制了痛觉肽活性，并且可用作镇痛剂，抗肥胖剂，脑功能改善剂，治疗阿尔茨海默病和痴呆症的药物，治疗精神分裂症和神经退行性疾病的药物，抗抑郁剂，治疗尿崩症，多尿症，低血压等的药物。
• Catalyst and process for hydrogenating olefinically unsaturated compound
  申请人：JSR Corporation

  公开号：EP0974602A1

  公开（公告）日：2000-01-26

  A hydrogenation catalyst comprising (A) a transition metal compound in which a group having a heterocyclic skeleton is bonded to Ti, Zr or Hf through an oxygen atom or a nitrogen atom, a representative of which compound is bis(cyclopentadienyl)titanium bis(tetrahydrofurfuryloxy) and (B) an organic compound, halide or hydride of a metal of Groups I to III of the Periodic Table or comprising the constituent (A), the constituent (B) and (C) a polar, organic compound such as an alcohol, a carboxylic acid or the like. An olefinically unsaturated compound can be hydrogenated with a high efficiency by contacting the compound with hydrogen in the presence of the above catalyst in an inert, organic solvent. The above catalyst has a very high catalytic activity, is excellent in hydrogenation selectivity and thermal resistance, also excellent in storage stability and maintainability of catalytic activity and is hardly affected by the co-existing impurities.

  一种氢化催化剂，包括(A)一种过渡金属化合物，其中具有杂环骨架的基团通过氧原子或氮原子与 Ti、Zr 或 Hf 键合，该化合物的代表是双(环戊二烯基)双(四氢糠氧基)钛和(B)一种有机化合物、(C) 极性有机化合物，如醇、羧酸等。在惰性有机溶剂中，烯烃不饱和化合物在上述催化剂存在下与氢气接触，可以高效氢化。上述催化剂具有极高的催化活性，在氢化选择性和耐热性方面表现出色，在贮存稳定性和催化活性的可维持性方面也很出色，而且几乎不受共存杂质的影响。
• BENZIMIDAZOLE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1342717A1

  公开（公告）日：2003-09-10

  This invention relates to the compounds represented by a general formula [I]:    [in which A1 and A2 represent optionally fluorine-substituted methine or the like; B represents halogen, cyano, lower alkyl or the like; D represents optionally substituted heterocyclic group or the like; and G represents C3-C20 aliphatic group such as alicyclic group]. These compounds inhibit nociceptin activities due to their high affinity to nociceptin receptor, and are useful as analgesic, antiobestic, corebral function improver, drugs for treatment of alzheimer's disease and dementia, remedies for schizophrenia and neurodegenerative diseases, antidepressant, remedies for diabetes insipidus, polyuria, hypotension and so on.

  本发明涉及通式[I]所代表的化合物： [其中 A1 和 A2 代表任选氟取代的甲基或类似物；B 代表卤素、氰基、低级烷基或类似物；D 代表任选取代的杂环基团或类似物；G 代表 C3-C20 脂肪族基团，例如脂环族基团]。这些化合物由于与痛觉素受体的高亲和力而抑制痛觉素的活性，可用作镇痛剂、抗镇静剂、改善大脑核心功能的药物、治疗老年痴呆症和痴呆症的药物、治疗精神分裂症和神经退行性疾病的药物、抗抑郁剂、治疗糖尿病、多尿、低血压等。
• Room Temperature Intramolecular Hydro-O-alkylation of Aldehydes:  sp³ C−H Functionalization via a Lewis Acid Catalyzed Tandem 1,5-Hydride Transfer/Cyclization
  作者：Stefan J. Pastine、Dalibor Sames

  DOI：10.1021/ol0522283

  日期：2005.11.1

  The scope and limitations of intramolecular hydro-O-alkylation of aldehyde substrates leading to spiroketals and bicyclic ketals and aminals is reported. The direct transformation of tertiary and sterically hindered secondary sp(3) C-H bonds into C-O bonds under the action of a catalytic amount of a variety of Lewis acids is described. The mechanism of these transformations is proposed to involve a tandem hydride transfer/cyclization sequence.